 NEWARK, N.J., Sept. 17, 2021 PRNewswire -- Rafael Holdings, Inc., NYSE: RFL, a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced today it made a grant to Patrick Fabbio of options to purchase 105,602 shares of Class B common stock of the Company with an exercise price equal to 36.32, the closing price of the Class B common stock on September 16, 2021, the trading day prior to the grant. 